

Prescribing of Wound Management products on FP10

This document clarifies the situations where primary care prescribers may prescribe wound management products on FP10 prescription.

All wound management products on the [Sussex Partner Formulary](#) have been selected, following research and review of available clinical evidence and approved by the Area Prescribing Committee and are expected to provide treatment options for most situations.

The formulary wound management products are available to order via Online Non-Prescription Ordering Service (ONPOS) provided as a stock for immediate use without the need for a prescription. Wound management products are supplied by NHS Supply Chain (NHSSC) and North West Ostomy Supplies (NWOS).

The principles for prescribing are:

Prescriptions (FP10s) should not be routinely used as a route for formulary or non-formulary wound management prescribing.

1. Formulary products should be ordered via ONPOS.
2. Prescription requests from Community Nurses (DNs), Practice Nurses (PNs) and Nursing Home staff for non-formulary products should not be prescribed. Patients transferred from another practice or care setting with non-formulary dressings should be reassessed for a formulary product (see point 4 and 5 for exceptions)
3. In exceptional circumstances Tissue Viability Nurse Specialist (TVNs) may write a clinical rationale for prescribing a non-formulary item on FP10. The TVNs will also inform the Sussex ICB wound care team at: sxicb.mo.woundcare@nhs.net
4. Prescriptions can be issued for patients with rare conditions requiring tertiary oversight and an individualised care plan. This includes people with Epidermolysis Bullosa (EB) and other diagnosed conditions from tertiary centres who will recommend suitable products to use.
5. Fungating tumours may require additional products to be prescribed. Specialist advice should be accessed from the TVNs or the Palliative care team for recommended products for symptom control.

6. FP10's should not be issued for a temporary dressing replacement where a stock shortage of the formulary product has occurred. Where the shortages are anticipated to be a long-term issue, alternatives will be managed by the Sussex ICB wound care team and provided via ONPOS.

Self-care

7. Patients receiving long-term prescriptions for wound management products while declining regular clinical review are currently described as self-care.

These patients should be reviewed every 3 months as a minimum, to ensure the products are still clinically appropriate. It would be suitable for these patients to have a limited supply available to reorder on repeat FP10 until the next clinical review. We would not expect a patient to attend the practice to solely collect wound management products from the ONPOS stock.

The Sussex wound care team (part of the Medicines Optimisation Team) are available to support prescribers and explain the process for requesting additions to the Sussex Partner Formulary via the dedicated email: sxib.mo.woundcare@nhs.net